- Home
- PRA vs NRIX Comparison
PRA vs NRIX Comparison
Compare PRA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRA
- NRIX
- Stock Information
- Founded
- PRA 1976
- NRIX 2009
- Country
- PRA United States
- NRIX United States
- Employees
- PRA N/A
- NRIX N/A
- Industry
- PRA Property-Casualty Insurers
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- PRA Finance
- NRIX Health Care
- Exchange
- PRA Nasdaq
- NRIX Nasdaq
- Market Cap
- PRA 1.2B
- NRIX 970.1M
- IPO Year
- PRA N/A
- NRIX 2020
- Fundamental
- Price
- PRA $23.80
- NRIX $11.52
- Analyst Decision
- PRA Hold
- NRIX Strong Buy
- Analyst Count
- PRA 4
- NRIX 16
- Target Price
- PRA $21.00
- NRIX $29.56
- AVG Volume (30 Days)
- PRA 698.2K
- NRIX 977.7K
- Earning Date
- PRA 08-07-2025
- NRIX 07-09-2025
- Dividend Yield
- PRA N/A
- NRIX N/A
- EPS Growth
- PRA N/A
- NRIX N/A
- EPS
- PRA 0.83
- NRIX N/A
- Revenue
- PRA $1,140,267,000.00
- NRIX $88,381,000.00
- Revenue This Year
- PRA N/A
- NRIX $34.87
- Revenue Next Year
- PRA $0.58
- NRIX N/A
- P/E Ratio
- PRA $28.74
- NRIX N/A
- Revenue Growth
- PRA N/A
- NRIX 41.86
- 52 Week Low
- PRA $11.27
- NRIX $8.18
- 52 Week High
- PRA $23.95
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- PRA 70.61
- NRIX 46.09
- Support Level
- PRA $23.76
- NRIX $11.13
- Resistance Level
- PRA $23.95
- NRIX $11.92
- Average True Range (ATR)
- PRA 0.11
- NRIX 0.75
- MACD
- PRA -0.01
- NRIX -0.13
- Stochastic Oscillator
- PRA 50.00
- NRIX 11.50
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.